Loading...

GenSight Biologics : Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Print Friendly, PDF & Email

LHON RELATED: First publication based on Phase III data to document sustained and clinically meaningful bilateral improvement in visual acuity from unilateral injection of a gene therapy Non-human primate study clarifies mechanism behind contralateral effect Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on […]